Business Context and Reporting Period
Company: Metavia Inc. (MTVA)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Metavia is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. Its primary programs are DA-1241 (a GPR119 agonist for MASH and Type 2 Diabetes) and DA-1726 (a dual GLP-1/GCGR agonist for obesity). The company has no product revenue and relies on capital raising to fund operations.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,995) | $(10,053) | $(7,666) | $(16,767) |
| Loss Per Share (Basic/Diluted) | $(0.26) | $(1.85) | $(0.60) | $(3.19) |
| Operating Expenses | $4,301 | $10,084 | $8,187 | $16,965 |
| Cash and Cash Equivalents (End of Period) | $17,589 | $27,934 | $17,589 | $27,934 |
| Net Cash Used in Operating Activities | N/A | N/A | $(7,886) | $(13,693) |
| Net Cash Provided by Financing Activities | N/A | N/A | $9,460 | $19,200 |
| Accumulated Deficit | $(143,523) | $(125,032) | $(143,523) | $(125,032) |
Note: Revenue is $0 as the company is pre-commercial. Figures in thousands.
Material Changes vs. Prior Period
- Significant Expense Reduction: Total operating expenses decreased by 57.3% in Q2 2025 ($4.3M) compared to Q2 2024 ($10.1M). This was driven primarily by a 71.3% reduction in Research and Development (R&D) expenses ($2.3M vs. $8.1M), attributed to lower direct costs for DA-1241 and DA-1726 clinical trials.
- Improved Net Loss: Net loss narrowed significantly to $4.0M in Q2 2025 from $10.1M in Q2 2024. For the six-month period, the loss decreased to $7.7M from $16.8M.
- Capital Raise: In May 2025, the company closed a private placement with related parties (Dong-A ST and affiliate) raising gross proceeds of $10.0 million. This included the issuance of common stock and pre-funded warrants, which were subsequently exercised.
- Warrant Liability Gain: The company recorded a gain of $0.2M in Q2 2025 from the change in fair value of warrant liabilities, compared to a loss of $0.1M in the prior year quarter.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. With $17.6M in cash and an accumulated deficit of $143.5M, the company expects to continue incurring losses and negative cash flows. They plan to fund operations through equity offerings, debt, or collaborations, but there is no assurance of success.
- Clinical Progress:
- DA-1241: Finalizing the Clinical Study Report for the Phase 2a trial in MASH. Positive top-line results were announced in December 2024. The company is working to schedule an end-of-Phase 2 meeting with the FDA.
- DA-1726: Phase 1 trial is ongoing. Positive data from the multiple ascending dose (MAD) Part 2 study was announced in April 2025. Enrollment for a higher-dose cohort began in late June 2025, with top-line data expected in Q4 2025.
- Recent Developments: In August 2025, Metavia announced a research collaboration with Syntekabio, Inc., an AI-driven drug discovery company, to optimize DA-1241.
- Internal Controls: Previously identified material weaknesses regarding logical access to accounting software and review of accrued clinical trial liabilities have been remediated as of June 30, 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $17.6M cash balance to fund operations into 2026 given the ongoing clinical trial costs for DA-1241 and DA-1726.
- Related Party Transactions: Review the terms of the license and shared services agreements with Dong-A ST, which account for a significant portion of R&D expenses ($2.4M in 6M 2025) and related party payables ($3.7M).
- Warrant Liability Volatility: Monitor the fair value of outstanding warrant liabilities, which fluctuate based on stock price and impact net income/loss.
- Regulatory Milestones: Track the timing of the FDA end-of-Phase 2 meeting for DA-1241 and the Q4 2025 data readout for the DA-1726 high-dose cohort.
- Dilution Risk: Assess the potential for significant shareholder dilution if the company requires additional equity financing to maintain its going concern status.